Product
Placebo for TransCon CNP
2 clinical trials
1 indication
Indication
AchondroplasiaClinical trial
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2022-09-27
Clinical trial
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2024-08-01